Literature DB >> 25912591

Exendin-4, glucagon-like peptide-1 receptor agonist, enhances isoflurane-induced preconditioning against myocardial infarction via caveolin-3 expression.

E Hamaguchi1, K Tanaka, R Tsutsumi, Y Sakai, K Fukuta, A Kasai, Y M Tsutsumi.   

Abstract

OBJECTIVE: To investigate the cardioprotective effects of isoflurane and exendin-4 against myocardial ischemia/reperfusion injury and the signaling pathways through which these effects are mediated.
MATERIALS AND METHODS: For infarct size measurements, anesthetized mice were subjected to 30 min of coronary artery occlusion followed by 2 h of reperfusion. Wild-type or caveolin-3 knockout mice received isoflurane, exendin-4, or isoflurane with exendin-4 before ischemia index determination. Caveolin-3 expression in the heart was measured by immunoblotting.
RESULTS: Myocardial infarct size was smaller in the isoflurane- [1.0 minimum alveolar concentration (MAC)] or exendin-4- (30 ng/kg i.v.) treated groups than the controls. Infarct size was not affected by isoflurane at 0.5 MAC or 3 ng/kg i.v. exendin-4, but the combination of these treatments reduced infarct size. Pharmacological preconditioning (isoflurane at 1.0 MAC, 30 ng/kg i.v. exendin-4, or isoflurane at 0.5 MAC with 3 ng/kg i.v. exendin-4) increased caveolin-3 protein expression in the heart after infarct induction. The cardioprotective effects of isoflurane, exendin-4, and isoflurane with exendin-4 were abolished in caveolin-3 knockout mice.
CONCLUSIONS: The combination of isoflurane and exendin-4 reduced infarct size, but it was not more effective than either agent alone, and the cardioprotective effects of these agents are mediated by caveolin-3 expression.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25912591

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  5 in total

Review 1.  New Therapeutic Options for Type 2 Diabetes Mellitus and Their Impact Against Ischemic Heart Disease.

Authors:  Malak Almutairi; Jordan S F Chan; John R Ussher
Journal:  Front Physiol       Date:  2022-06-27       Impact factor: 4.755

2.  Plasma from Volunteers Breathing Helium Reduces Hypoxia-Induced Cell Damage in Human Endothelial Cells-Mechanisms of Remote Protection Against Hypoxia by Helium.

Authors:  Kirsten F Smit; Gezina T M L Oei; Moritz Konkel; Quinten J J Augustijn; Markus W Hollmann; Benedikt Preckel; Hemal H Patel; Nina C Weber
Journal:  Cardiovasc Drugs Ther       Date:  2019-06       Impact factor: 3.727

Review 3.  Research Progress on the Cardiovascular Protective Effect of Glucagon-Like Peptide-1 Receptor Agonists.

Authors:  Rui Song; Hang Qian; Yunlian Wang; Qingmei Li; Dongfeng Li; Jishun Chen; Jingning Yang; Jixin Zhong; Handong Yang; Xinwen Min; Hao Xu; Yong Yang; Jun Chen
Journal:  J Diabetes Res       Date:  2022-04-08       Impact factor: 4.061

4.  DPP-4 inhibition by linagliptin prevents cardiac dysfunction and inflammation by targeting the Nlrp3/ASC inflammasome.

Authors:  Yochai Birnbaum; Dat Tran; Mandeep Bajaj; Yumei Ye
Journal:  Basic Res Cardiol       Date:  2019-08-06       Impact factor: 17.165

5.  Helium alters the cytoskeleton and decreases permeability in endothelial cells cultured in vitro through a pathway involving Caveolin-1.

Authors:  Kirsten F Smit; Moritz Konkel; Raphaela Kerindongo; Maximilian A Landau; Coert J Zuurbier; Markus W Hollmann; Benedikt Preckel; Rienk Nieuwland; Martin Albrecht; Nina C Weber
Journal:  Sci Rep       Date:  2018-03-19       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.